Biotech · Private company
Tempus AI
Track this companyFree. Adds Tempus AI to your Dealase workspace and tells you when its record changes.
Clinical trials2217 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- NiraparibPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Automated alertAortic Valve StenosisClinicalTrials.gov · fetched Nov 12, 2026
- ECG-based AI Device - Results Not Returned to InvestigatorPulmonary HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- ECG-based AI Device - Results Returned to InvestigatorPulmonary HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- EchocardiogramAtrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- Echocardiogram and Right Heart CatheterizationPulmonary HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- None - Observational StudyAcute Myeloid Leukaemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- ObservationBreast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ObservationColorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- ObservationNon-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ObservationSmall Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- There are no interventions in this observational study.Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Zio Patch MonitorAtrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in CancerRECRUITING · started Aug 1, 2026ClinicalTrials.gov NCT07756034 · fetched Nov 12, 2026
- A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk MyelofibrosisPHASE1 · RECRUITING · started May 21, 2026ClinicalTrials.gov NCT07250646 · fetched Nov 12, 2026
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesRECRUITING · started Jan 27, 2026ClinicalTrials.gov NCT07154823 · fetched Nov 12, 2026
- Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesRECRUITING · started Oct 27, 2025ClinicalTrials.gov NCT07211178 · fetched Nov 12, 2026
- Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionNA · RECRUITING · started Jul 23, 2025ClinicalTrials.gov NCT06911632 · fetched Nov 12, 2026
- NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) TrialNA · RECRUITING · started Sep 16, 2024ClinicalTrials.gov NCT06511505 · fetched Nov 12, 2026
- Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR PlatformNA · COMPLETED · started Aug 27, 2024ClinicalTrials.gov NCT06099665 · fetched Nov 12, 2026
- A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT06163534 · fetched Nov 12, 2026
- TEMPUS ARIES: A Biobank Registry Platform Study in OncologyRECRUITING · started Jun 26, 2024ClinicalTrials.gov NCT06207032 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionPHASE1_PHASE2 · RECRUITING · started Apr 3, 2024ClinicalTrials.gov NCT06051695 · fetched Nov 12, 2026
- Umbrella Study for Analysis of Data Related to Patients With CancerCOMPLETED · started Dec 6, 2023ClinicalTrials.gov NCT06018753 · fetched Nov 12, 2026
- Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.TERMINATED · started Dec 1, 2023ClinicalTrials.gov NCT06126003 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 28, 2023ClinicalTrials.gov NCT05736731 · fetched Nov 12, 2026
- Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart DiseaseNA · UNKNOWN · started Sep 7, 2022ClinicalTrials.gov NCT05442203 · fetched Nov 12, 2026
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)RECRUITING · started Jul 13, 2022ClinicalTrials.gov NCT05257551 · fetched Nov 12, 2026
- GEMINI-NSCLC: NSCLC Biomarker StudyRECRUITING · started Jun 22, 2022ClinicalTrials.gov NCT05236114 · fetched Nov 12, 2026
- Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS AssaysRECRUITING · started Jun 21, 2022ClinicalTrials.gov NCT05234177 · fetched Nov 12, 2026
- Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsPHASE2 · TERMINATED · started Mar 15, 2022ClinicalTrials.gov NCT05169437 · fetched Nov 12, 2026
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRECRUITING · started Oct 29, 2021ClinicalTrials.gov NCT04981119 · fetched Nov 12, 2026
- PRediction Of Glycemic RESponse StudyACTIVE_NOT_RECRUITING · started Jun 8, 2021ClinicalTrials.gov NCT04881019 · fetched Nov 12, 2026
- Tempus Priority Study: A Pan-tumor Observational StudyACTIVE_NOT_RECRUITING · started Oct 19, 2020ClinicalTrials.gov NCT05179824 · fetched Nov 12, 2026
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)PHASE2 · ACTIVE_NOT_RECRUITING · started May 13, 2014ClinicalTrials.gov NCT02152254 · fetched Nov 12, 2026